Clinical trials
Gastric or Gastroesophageal Junction Adenocarcinoma clinical trials
Below are recruiting gastric or gastroesophageal junction adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 962 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07624383Recruiting
New topical treatment for nonerosive acid reflux disease
This study tests a new topical treatment for people with chronic heartburn and acid regurgitation who don't have erosions (damage) in their esophagus. The treatment is applied directly to the affected area and may help relieve symptoms without taking daily pills.
Warsaw, Masovian VoivodeshipAges 18 years+ - NCT06711471RecruitingPhase 2
Combination therapy for advanced stomach cancer after prior treatments
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07464756RecruitingPhase 2
Study of SHR-1701 and apatinib with chemo before stomach cancer surgery
This trial tests whether adding SHR-1701 (an immunotherapy) with or without apatinib (a targeted therapy) to standard chemotherapy before surgery can help treat gastric cancer. It is for people with stomach or gastroesophageal junction cancer that has spread to nearby lymph nodes but is still removable.
Nanjing, JiangsuAges 18 years+ - NCT07429487Recruiting
Smartwatch activity tracking for fatigue after chemo
This study uses a smartwatch to track your physical activity and see if it helps reduce tiredness after finishing chemotherapy. It is for people who finished treatment for certain cancers less than 3 months ago.
NiceAges 18–75 - NCT07392346RecruitingPhase 2
Fruquintinib combo for advanced gastric cancer after immunotherapy
This trial tests a combination of targeted therapy (fruquintinib), chemotherapy (nab-paclitaxel), and two immunotherapies (iparomlimab and tuvonralimab) for people with advanced stomach or gastroesophageal junction cancer whose first treatment with a PD-1/PD-L1 inhibitor stopped working. The goal is to see if this new combination can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06289374Recruiting
Long-term breath & blood study after stomach or esophagus cancer surgery
This study is for people who have had surgery for stomach or esophagus adenocarcinoma and are already part of a larger study called BIORESOURCE 1. It looks at certain substances in your breath and blood over time to learn more about recovery.
LondonAges 18–90 - NCT05303714RecruitingPhase 3
PIPAC plus chemo for limited peritoneal stomach cancer
This trial tests a treatment called PIPAC (medicine delivered into the abdomen through a small scope) along with “multimodal” therapy, including chemotherapy, for stomach cancer that has spread only in the lining of the abdomen in limited amounts. It may help control the cancer and prevent progression after surgery.
VeronaAges 18–75 - NCT07270991RecruitingPhase 3
Testing a new drug combo for advanced stomach or esophageal cancer
This study tests whether adding a targeted drug, fruquintinib, to the chemotherapy trifluridine/tipiracil works better than the chemotherapy alone for stomach or esophageal cancer that has spread. It's for people who have already tried a few treatments.
AurillacAges 18 years+ - NCT07263386RecruitingPhase 2
Immunotherapy plus chemo for PD-L1-positive stomach cancer
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) after surgery helps prevent stomach cancer from returning. It’s for people whose tumors have a protein called PD-L1 and who had cancer in at least 7 lymph nodes.
Nanjing, JiangsuAges 18–75 - NCT07219238RecruitingPhase 2/Phase 3
PET scan for cancer spread in the abdomen
This trial tests a new PET/CT scan using a special tracer to detect cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis) in people with colorectal, stomach, ovarian, or pancreatic cancer. It aims to see if this scan is better at finding the spread than standard imaging.
Grand Rapids, MichiganAges 18 years+ - NCT07178808RecruitingPhase 2
Surgery and heated chemotherapy for stomach cancer
This trial tests if surgery to remove visible cancer in the belly combined with heated chemotherapy placed directly into the abdomen can help people with stomach cancer that has spread to the lining of the belly. It is for patients who are well enough to undergo major surgery and meet specific health requirements.
Gilbert, ArizonaAges 18 years+ - NCT07165847RecruitingPhase 2
Combination therapy before surgery for gastric cancer
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs before surgery for people with resectable gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Chongqing, Other (Non U.s.)Ages 18 years+ - NCT07098026Recruiting
Herbal mixture plus chemo before surgery for advanced stomach cancer
This trial tests whether adding an herbal mixture (Shenqi Fuwei Mixture) to standard chemotherapy before surgery can help treat locally advanced stomach cancer. It is for people whose cancer has not spread to distant sites and who are healthy enough to undergo treatment and surgery.
Changsha, HunanAges 18–75 - NCT07103668RecruitingPhase 3
Study of a new drug for advanced stomach cancer after prior treatments
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
BeijingAges 18 years+ - NCT07034742RecruitingEarly Phase 1
MRD testing after stomach cancer surgery
This study looks at whether a blood test for leftover cancer cells (called MRD) after stomach cancer surgery can help guide treatment. It is for people with a certain type of stomach cancer that has spread to nearby tissues but not to distant organs, and who are having surgery as their first treatment.
BeijingAges 18–75 - NCT07029269RecruitingPhase 3
Recovery without drainage tubes after stomach cancer surgery
This trial tests whether it is safe and helpful to skip placing drainage tubes in the abdomen after keyhole surgery to remove part of the stomach for gastric cancer. It aims to speed up recovery and reduce discomfort.
Beijing, Beijing MunicipalityAges 18–80 - NCT07007182RecruitingPhase 2
Treating stomach cancer spread to lymph nodes with chemo, surgery, and radiation
This trial tests a combination of chemotherapy (conversion therapy), surgery, and radiation for people with stomach cancer that has spread only to lymph nodes behind the stomach. The goal is to see if this approach can help shrink the cancer and improve outcomes.
Jinan, ShandongAges 18–75 - NCT06199895RecruitingPhase 2
Study of paclitaxel for patients with taxane-resistant solid tumors
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
Wuhan, HubeiAges 18 years+ - NCT06957678Enrolling by invitation
AI predicts lymph node spread in stomach cancer using scans and biopsy
This study uses artificial intelligence to predict whether stomach cancer has spread to nearby lymph nodes. By analyzing your CT/MRI scans and biopsy results before surgery, the AI may help doctors plan your treatment more precisely.
Shijiazhuang, None SelectedAges 18–80 - NCT06937567RecruitingEarly Phase 1
CDH17 car-t therapy for advanced solid tumors
This trial tests a new treatment called CDH17 CAR-T for people with advanced solid tumors like colorectal, stomach, pancreatic, or bile duct cancer. It is for patients who have tried other treatments without success. The therapy uses your own immune cells, modified to target a protein called CDH17 found on some cancer cells.
Hangzhou, ZhejiangAges 18–70 - NCT06932068RecruitingPhase 2
Study of new drug combo for advanced stomach cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab/tuvonralimab) plus chemotherapy (XELOX) in people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has low PD-L1 levels. It aims to see if this treatment can help shrink tumors or slow the disease.
Zhengzhou, HenanAges 18–75 - NCT06862479Enrolling by invitation
Comparing a stent to other endoscopic leak treatments
This trial compares a special stent (the Luso-Cor Stent) to other endoscopic procedures to treat leaks or abnormal connections after certain stomach or esophageal surgeries. It aims to find the best way to fix these complications using a scope.
Lisbon, Lisbon DistrictAges 18 years+ - NCT04592211RecruitingPhase 1/Phase 2
Study pembrolizumab plus olaparib for stomach cancer after treatment
This Phase 1/2 study tests whether combining pembrolizumab (an immunotherapy) with olaparib (a targeted cancer pill) can shrink or control recurrent or advanced stomach and GEJ cancer. You may be eligible if your cancer has already been treated with trastuzumab and certain body-function and blood/vital checks look safe.
SeoulAges 19 years+ - NCT06675136RecruitingPhase 1
Nab-paclitaxel PIPAC with paclitaxel and ramucirumab for stomach cancer spread to belly lining
This trial tests a new way to deliver chemotherapy directly into the belly for stomach cancer that has spread to the lining of the abdomen (peritoneal metastases). It also combines two standard chemotherapy drugs. The goal is to see if this approach can help people whose cancer progressed after first treatment.
Duarte, CaliforniaAges 18 years+
Hear when a new Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastric or gastroesophageal junction adenocarcinoma?
- Yes. Clin2 currently lists 962 recruiting gastric or gastroesophageal junction adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastric or gastroesophageal junction adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastric or gastroesophageal junction adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastric / Gastroesophageal Junction Adenocarcinoma
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma
- Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Advanced Gastroesophageal Junction Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.